SMT201300109B - Imidazopiridazincarbonitrili utili come inibitori di chinasi - Google Patents

Imidazopiridazincarbonitrili utili come inibitori di chinasi

Info

Publication number
SMT201300109B
SMT201300109B SM201300109T SM201300109T SMT201300109B SM T201300109 B SMT201300109 B SM T201300109B SM 201300109 T SM201300109 T SM 201300109T SM 201300109 T SM201300109 T SM 201300109T SM T201300109 B SMT201300109 B SM T201300109B
Authority
SM
San Marino
Prior art keywords
useful
imidazopyridazincarbonitriles
kinase inhibitors
formula
imidazopyridazines
Prior art date
Application number
SM201300109T
Other languages
English (en)
Italian (it)
Inventor
Brian Fink
Libing Chen
Ashvinikumar Gavai
Liqi He
Soong-Hoon Kim
Andrew Nation
Yufen Zhao
Litai Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT201300109B publication Critical patent/SMT201300109B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
SM201300109T 2008-10-09 2013-10-02 Imidazopiridazincarbonitrili utili come inibitori di chinasi SMT201300109B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10404508P 2008-10-09 2008-10-09
PCT/US2009/059968 WO2010042699A1 (en) 2008-10-09 2009-10-08 Imidazopyridazinecarbonitriles useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
SMT201300109B true SMT201300109B (it) 2013-11-08

Family

ID=41718919

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300109T SMT201300109B (it) 2008-10-09 2013-10-02 Imidazopiridazincarbonitrili utili come inibitori di chinasi

Country Status (28)

Country Link
US (3) US8252795B2 (ja)
EP (1) EP2350081B1 (ja)
JP (1) JP5560278B2 (ja)
KR (1) KR20110075010A (ja)
CN (1) CN102245609B (ja)
AR (1) AR073818A1 (ja)
AU (1) AU2009302360B2 (ja)
BR (1) BRPI0920135A2 (ja)
CA (1) CA2739782A1 (ja)
CL (1) CL2011000777A1 (ja)
CO (1) CO6361936A2 (ja)
CY (1) CY1114539T1 (ja)
DK (1) DK2350081T3 (ja)
EA (1) EA018163B1 (ja)
ES (1) ES2426951T3 (ja)
HK (1) HK1154002A1 (ja)
HR (1) HRP20130787T1 (ja)
IL (1) IL211693A (ja)
MX (1) MX2011003304A (ja)
NZ (1) NZ591712A (ja)
PE (1) PE20110411A1 (ja)
PL (1) PL2350081T3 (ja)
PT (1) PT2350081E (ja)
SI (1) SI2350081T1 (ja)
SM (1) SMT201300109B (ja)
TW (1) TWI491610B (ja)
WO (1) WO2010042699A1 (ja)
ZA (1) ZA201102423B (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
JP5824065B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
WO2012080232A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140323519A1 (en) * 2011-04-26 2014-10-30 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
WO2014198647A2 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR20180081584A (ko) 2015-11-18 2018-07-16 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CA3028727A1 (en) 2016-06-24 2017-12-28 Polaris Pharmaceuticals, Inc. Ck2 inhibitors, compositions and methods thereof
MA45940A (fr) * 2016-08-10 2019-06-19 Takeda Pharmaceuticals Co Composé hétérocyclique
CN110191887B (zh) 2016-11-17 2022-02-18 百时美施贵宝公司 IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
PE20200008A1 (es) 2017-03-30 2020-01-06 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2019128871A1 (zh) 2017-12-29 2019-07-04 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
US20200329707A1 (en) 2017-12-29 2020-10-22 Jiangsu Flag Chemical Industry Co., Ltd. Pyrazolamide compound having insecticidal activity and use thereof
CN109988150B (zh) 2017-12-29 2022-04-12 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
SG11202006832YA (en) * 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP2022526901A (ja) 2019-03-19 2022-05-27 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 駆虫性アザベンゾチオフェンおよびアザベンゾフラン化合物
EP3958865A1 (en) 2019-04-24 2022-03-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2020216773A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
KR20220004103A (ko) 2019-04-24 2022-01-11 바이엘 악티엔게젤샤프트 4H-피롤로[3,2-c]피리딘-4-온 화합물
WO2021198020A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
PE20231205A1 (es) 2020-05-29 2023-08-17 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos
WO2023147372A1 (en) * 2022-01-25 2023-08-03 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
WO2024039767A1 (en) * 2022-08-18 2024-02-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
WO2001083481A1 (fr) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazopyridine
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
ATE362475T1 (de) * 2003-12-31 2007-06-15 Schering Plough Ltd Bekämpfng von parasiten in tieren durch anwendung von imidazo(1,2-b)pyridazinderivaten
US20090023737A1 (en) 2004-02-12 2009-01-22 Neurogen Corporation Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands
CN101048158A (zh) * 2004-08-13 2007-10-03 健泰科生物技术公司 利用atp的酶的噻唑－类抑制剂
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
US20070185063A1 (en) 2005-08-23 2007-08-09 Idenix Pharmaceuticals, Inc. Seven-membered ring nucleosides
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
MX2009001349A (es) * 2006-08-04 2009-04-17 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso.
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
US20110021513A1 (en) 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1911451A1 (en) * 2006-10-10 2008-04-16 INSERM (Institut National de la Santé et de la Recherche Medicale) Protein-kinase CK2 inhibitors and their therapeutic applications
WO2008052733A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
AU2008250328A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as PI3K lipid kinase inhibitors
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Also Published As

Publication number Publication date
HRP20130787T1 (en) 2013-09-30
TW201018686A (en) 2010-05-16
HK1154002A1 (en) 2012-04-13
JP5560278B2 (ja) 2014-07-23
NZ591712A (en) 2012-10-26
BRPI0920135A2 (pt) 2019-09-24
US9371328B2 (en) 2016-06-21
ES2426951T3 (es) 2013-10-25
EA018163B1 (ru) 2013-05-30
PT2350081E (pt) 2013-09-24
TWI491610B (zh) 2015-07-11
CN102245609B (zh) 2016-03-09
PL2350081T3 (pl) 2013-10-31
AU2009302360B2 (en) 2014-12-11
AU2009302360A1 (en) 2010-04-15
EP2350081B1 (en) 2013-07-03
US8252795B2 (en) 2012-08-28
CO6361936A2 (es) 2012-01-20
CN102245609A (zh) 2011-11-16
WO2010042699A1 (en) 2010-04-15
US20120283241A1 (en) 2012-11-08
DK2350081T3 (da) 2013-10-14
CL2011000777A1 (es) 2011-08-12
CA2739782A1 (en) 2010-04-15
SI2350081T1 (sl) 2013-11-29
EA201100580A1 (ru) 2011-10-31
CY1114539T1 (el) 2016-10-05
EP2350081A1 (en) 2011-08-03
IL211693A0 (en) 2011-06-30
US20140179674A1 (en) 2014-06-26
MX2011003304A (es) 2011-04-21
ZA201102423B (en) 2012-09-26
US20100113458A1 (en) 2010-05-06
AR073818A1 (es) 2010-12-01
KR20110075010A (ko) 2011-07-05
PE20110411A1 (es) 2011-06-22
JP2012505235A (ja) 2012-03-01
IL211693A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
DK1761520T3 (da) Kinaseinhibitorer
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201490949A1 (ru) Ингибиторы киназ
TN2011000293A1 (en) Protein kinase inhibitors
BR112013016595A2 (pt) inibidores de neprilisina
EA201270590A1 (ru) Ингибиторы акт
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201170832A1 (ru) Пуриновые соединения
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
EA200801199A1 (ru) Ингибиторы киназы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
DOP2005000010A (es) Inhibidores de quinasa
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
EA201270728A1 (ru) Пуриновые соединения
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
ATE548364T1 (de) Aminopyrazolkinasehemmer